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Abstract
Background: Enzalutamide and abiraterone acetate plus prednisone, which target the
androgen receptor axis, have expanded the treatment of advanced prostate cancer.
Retrospective analyses suggest some cross-resistance between these two drugs when
used sequentially, but robust, prospective studies have not yet been reported.
Objective: To fulﬁl a regulatory postregistration commitment by evaluating the efﬁcacy
and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer
(mCRPC) who progressed following abiraterone acetate plus prednisone treatment.
Design, setting, and participants: Multicentre, single-arm, open-label study, enrolled
patients with progressing mCRPC after 24 wk of abiraterone acetate plus prednisone
treatment. All patients maintained castration therapy during the trial. Prior chemother-
apy was allowed but not required.
Intervention: Patients received enzalutamide 160 mg/d orally.
Outcomemeasurements and statistical analysis: The primary endpoint was radiograph-
ic progression-free survival. Secondary endpoints were overall survival, prostate-spe-
ciﬁc antigen (PSA) response, and time-to-PSA progression. Safety data were also
assessed. Kaplan-Meier methods were used to descriptively analyse time-to-event
endpoints.
Results and limitations: Overall, 214 patients received enzalutamide treatment, 145 of
whom were chemotherapy-naïve. Median radiographic progression-free survival was
8.1mo (95% conﬁdence interval: 6.1–8.3); median overall survival had not been reached.
Unconﬁrmed PSA response rate was 27% (48 of 181). Median time-to-PSA progression
was 5.7 mo (95% conﬁdence interval: 5.6–5.8). The most common treatment-emergent
adverse events were fat
(16(17%), and arthralgiay An employee of Medivati
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Conclusions: Enzalutamide showed antitumour activity in some patients with mCRPC who
had previously progressed following 24 wk of abiraterone acetate plus prednisone
treatment.
Patient summary: Patients with [18_TD$DIFF]mCRPC who progressed on previous abiraterone acetate
plus prednisone treatment, with or without prior chemotherapy, received enzalutamide.
Although cross-resistance between the two agents was observed in a majority of patients,
some still beneﬁted from enzalutamide treatment.
© 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer remains the second most common form of
cancer among men worldwide [1], and the management of
these patients continues to change with the approval of
targeted agents such as enzalutamide and abiraterone
acetate [2].
Enzalutamide is an androgen receptor inhibitor approved
for treating patients with metastatic castration-resistant
prostate cancer (mCRPC) [3–5]. It acts by inhibiting the
binding of androgens to the androgen receptor, androgen-
receptor nuclear translocation, and androgen-receptor-me-
diatedDNAbinding [6]. Enzalutamide significantly prolonged
overall survival (OS) versus placebo for chemotherapy-naïve
menwithmCRPC andmenwho had progressed on docetaxel
therapy (PREVAIL andAFFIRM trials, respectively) [3,4]. Enza-
lutamide also significantly prolonged progression-free sur-
vival (PFS) versus bicalutamide in chemotherapy-naïve men
with non-metastatic prostate cancer (STRIVE) [7] andmCRPC
(STRIVE and TERRAIN) [5,7].
Abiraterone acetate is a steroidal 17a-hydroxylase/
17,20-lyase inhibitor approved in combination with pred-
nisone for treating patients with mCRPC [8,9]. Abiraterone
acetate plus prednisone (referred to from here on as
“abiraterone”) significantly prolongedOS versus prednisone
alone for chemotherapy-naïve men (COU-AA-302) [9] and
men who had progressed on docetaxel (COU-AA-301)
[8,10]. However, a more modest response to abiraterone
following progression on docetaxel and enzalutamide was
observed in a limited number of patients with mCRPC after
discontinuation from the AFFIRM trial, including <10% of
patients achieving50% decline inprostate-specific antigen
(PSA) on subsequent abiraterone [11,12]. Following the
publication of these results, the European Medicines
Agency requested the developers of enzalutamide to
conduct a study to assess the efficacy of enzalutamide in
patients who had progressed following abiraterone.
In response, this postregistration study (ClinicalTrials.
gov, NCT02116582) was performed to evaluate the efficacy
and safety of enzalutamide treatment in patients with
mCRPC following disease progression after at least 24 wk of
abiraterone.
2. Patients and methods
2.1. Study design
This phase 4, open-label, single-arm study of enzalutamide
enrolled patients with mCRPC who had progressive diseasefollowing prior abiraterone treatment frommultiple clinical
sites in Europe. The study protocol was approved by the
review boards of participating institutions, and the trial was
in accordance with the Declaration of Helsinki. Written
informed consent from the patients were obtained prior to
any study-related screening procedures.
Patients must have had metastatic disease (Supplemen-
tary data) and must have received a minimum of 24 wk of
abiraterone treatment and discontinued its use for 4 wk
prior to enzalutamide treatment in the study (this inclusion
criterion was an amendment to the initial study design).
Previous chemotherapy for prostate cancer was limited to
1 prior line of docetaxel, which must have been prior to
abiraterone treatment. Patients received enzalutamide
160 mg/d orally and continued ongoing androgen depriva-
tion with luteinising hormone-releasing hormone analo-
gues for the duration of the study, or had a bilateral
orchiectomy (Supplementary Fig. 1). More details regarding
the study methodology, including key inclusion and
exclusion criteria, are described in the Supplementary data.
2.2. Outcomes
The primary study endpoint was radiographic PFS (rPFS),
defined as the time from the first dose of enzalutamide to
objective evidence of radiographic disease progression or
death from any cause, whichever occurred first. Bone
disease progression was considered when 2 new lesions
were observed, but if progression was first observed at (or
before)[2_TD$DIFF] wk [19_TD$DIFF] 13, a confirmatory scan demonstrating 2 new
additional lesions had to be performed after 6 [20_TD$DIFF]wk. More
details regarding confirmation of rPFS are described in the
Supplementary data.
Secondary endpoints included: (1) OS, defined as the
time from first dose to death from any cause, (2) PSA
response, defined as 50% decrease from baseline in PSA,
which was a binary variable for achieving (or not achieving)
this criterion based on the lowest PSA value observed
postbaseline (response confirmation, defined as a second
consecutive PSA value obtained  [3_TD$DIFF] wk later, was not
required), and (3) time-to-PSA progression. More details of
secondary and exploratory endpoints are described in the
Supplementary data.
2.3. Procedures
PSA, soft tissue disease on computed tomography scan or
magnetic resonance imaging, and bone disease on radionu-
clide bone scans data were collected at baseline, [2_TD$DIFF]wk [19_TD$DIFF] 13, and
every 12 wk until the analysis data cut-off point or
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data were also collected throughout the study.
2.4. Statistical analyses
Kaplan-Meier methods were used to descriptively analyse
time-to-event endpoints (ie, rPFS, OS, and time-to-PSA
progression). A two-sided 95% confidence interval (CI) for
the median timewas estimated by using the Brookmeyer and
Crowley method. The 25th percentile and the 75th percentile
estimates were also provided, along with a two-sided 95% CI
for the 25th percentile, if the median was not reached.
Rate of50% decline of PSA from baselinewas calculated,
along with a two-sided 95% CI using the Clopper-Pearson
method based on exact binomial distribution.
The sample size (200 patients) was chosen based on
discussions with the European Medicines Agency and
practical considerations (Supplementary data). The criteria
used for data censoring are described in the Supplementary
data.
3. Results
3.1. Patient disposition, baseline characteristics, and disease
history
The study enrolled patients between May 23, 2014 andMay
8, 2015. As of the cut-off date of May 8, 2016, the median
follow-up period was 14 mo. Two-hundred-and-seventy-
two patients were screened for enrolment and signed an
informed consent form (Supplementary Fig. 1). Fifty-seven
patients failed screening, 215 were enrolled, and 214 re-
ceived at least one dose of enzalutamide. Of these,
69 patients had prior treatment with chemotherapy before
abiraterone and 145 patients were chemotherapy-naïve.
The primary reason for treatment discontinuation in the
overall population was disease progression (n = 140; 65%).
Other reasons for treatment discontinuation included
adverse events (n = 17; 7.9%), withdrawal by patient (n = 8;
3.7%), death (n = 7; 3.3%), protocol violation (n = 3; 1.4%),
and other reasons (n = 9; 4.2%).
Demographics and baseline characteristics were gen-
erally similar between patients with prior treatment with
chemotherapy before abiraterone and chemotherapy-
naïve patients (Table 1). Overall, the median duration
of previous abiraterone therapy was 54 wk (60 wk for
patients previously treated with chemotherapy before
abiraterone and 52 wk for chemotherapy-naïve patients;
Table 1).
3.2. Enzalutamide treatment duration
Themedian duration of enzalutamide treatmentwas 5.7mo
(quartiles: 2.8, 11) for the overall patient population, with
154 (72%), 99 (46%), 64 (30%), and 35 (16%) patients on
treatment at 3 mo, 6 mo, 9 mo, and 12 mo, respectively
(Supplementary Table 1). The median duration of enzalu-
tamide treatment was similar between patients previously
treated with chemotherapy before abiraterone and chemo-therapy-naïve patients (5.5 mo and 5.9 mo, respectively;
Supplementary Table 1).
3.3. rPFS
In the overall population, the median duration of rPFS was
8.1 mo (95% CI: 6.1–8.3; Fig. 1). The median duration of rPFS
was 7.9 mo (95% CI: 5.5–11) for patients previously treated
with chemotherapy before abiraterone and 8.1 mo (95% CI:
5.7–8.3) for chemotherapy-naïve patients.
Of the 141 disease progression events observed by the
cut-off date in the overall population, 101 (72%) were
radiographic progression events and 40 (28%) were deaths
that occurred before experiencing radiographic progression
(Fig. 1). The remaining 73 patients were censored, of which
45 (62%) discontinued treatment without fulfilling radio-
graphic progression criteria and were alive at the time of
data cut-off (Fig. 1, Supplementary Table 2). Fifty patients
previously treated with chemotherapy prior to abiraterone
experienced a progression event by the cut-off date, of
which 31 (62%) were radiographic events and 19 (38%) were
deaths. Ninety-one chemotherapy-naïve patients experi-
enced a progression event, of which 70 (77%) were
radiographic events and 21 (23%) were deaths.
3.4. OS
Median OS for the overall study population and for
chemotherapy-naïve patients were not yet reached at the
time of the data cut-off point due to the low number of
events (69 out of 214 patients in the overall population and
38 out of 145 chemotherapy-naïve patients had died from
any cause prior to the data cut-off; Fig. 2). Median OS for
patients previously treated with chemotherapy before
abiraterone was 18 mo (95% CI: 13–not yet reached), with
31 deaths prior to the data cut-off (Fig. 2).
3.5. Rate of 50% decline in PSA from baseline
Overall, in 181 patients with 1 postbaseline PSA assess-
ment, the unconfirmed rate of 50% PSA decline from
baseline was 27% (95% CI: 20–34), with 48 patients having a
50% decrease in PSA frombaseline prior to the data cut-off.
Thirty-three patients discontinued enzalutamide treatment
before having a postbaseline PSA assessment. The uncon-
firmed rate of 50% PSA decline from baseline was 28%
(16 of 57; 95% CI: 17–42) and 26% (32 of 124; 95% CI: 18–34)
for patients with previous chemotherapy and chemothera-
py-naïve patients, respectively (Fig. 3). This50% decline in
PSA from baseline was confirmed by a subsequent PSA
measurement in 35 of 48 patients.
3.6. PSA progression
The median time-to-PSA progression in the overall popula-
tion was 5.7 mo (95% CI: 5.6–5.8), with 105 patients
experiencing PSA progression (Fig. 4). Similar results were
observed in patients previously treated with chemotherapy
before abiraterone and chemotherapy-naïve patients
Table 1 – Baseline characteristics
Characteristic Previous chemotherapy (n = 69) Chemotherapy-naïve (n = 145) Total (n = 214)
Demographics
Race, n (%)
White 57 (83) 107 (74) 164 (77)
Black 0 2 (1.4) 2 (0.9)
Other 0 1 (0.69) 1 (0.47)
Missinga 12 (17) 35 (24) 47 (22)
Age, yr, n (%)
<65 9 (13) 15 (10) 24 (11)
65–74 33 (48) 66 (46) 99 (46)
75 27 (39) 64 (44) 91 (43)
Median (quartiles) 72 (67, 77) 73 (70, 78) 73 (69, 78)
ECOG, n (%), grade
0 28 (41) 72 (50) 100 (47)
1 41 (59) 72 (50) 113 (53)
2 0 1 (0.7) 1 (0.5)
PSA, mg/l, median (quartiles) 71 (28, 192) 53 (22, 143) 59 (23, 157)
Cancer-related disease history
Prostate cancer duration, yr, median (quartiles) 7.1 (4.4, 12) 6.8 (3.4, 12) 6.9 (3.7, 12)
Duration of prior abi,b wk, median (quartiles) 60 (38, 84) 52 (35, 68) 54 (35, 73)
Time from abi end to study treatment start,b d, n (%)
<28 1 (1.4) 3 (2.1) 4 (1.9)
28–90 58 (84) 132 (91) 190 (89)
91–180 7 (10) 10 (6.9) 17 (7.9)
>180 3 (4.3) 0 3 (1.4)
Total Gleason score at initial diagnosis, n (%)
Low (2–4) 1 (1.4) 3 (2.1) 4 (1.9)
Medium (5–7) 30 (44) 74 (51) 104 (49)
High (8–10) 32 (46) 61 (42) 93 (43)
Missing 6 (8.7) 7 (4.8) 13 (6.1)
Distant metastasis at initial diagnosis, n (%) 21 (30) 33 (23) 54 (25)
LHRHa initiation or bilateral orchiectomy relative to diagnosis of metastasis, n (%)
Before 39 (57) 83 (57) 122 (57)
After 30 (44) 62 (43) 92 (43)
Metastasis assessment at screening and cancer treatment history
Metastases,c n (%)
Yes 69 (100) 144 (99) 213 (100)
No 0 1 (0.7) 1 (0.5)
Metastases localisation, n (%)
Bone only 38 (55) 68 (47) 106 (50)
Soft tissue only 6 (8.7) 19 (13) 25 (12)
Both 25 (36) 57 (39) 82 (38)
Previous radiation therapy, n (%)
Yes 45 (65) 89 (61) 134 (63)
No 24 (35) 56 (39) 80 (37)
Largest PSA decline 50% while on abi
Yes 40 (58) 82 (57) 122 (57)
No 22 (32) 44 (30) 66 (31)
Unknown 7 (10) 19 (13) 26 (12)
Responsive to abi for metastatic disease,d n (%)
Yes 18 (26) 35 (24) 53 (25)
No 31 (45) 45 (31) 76 (36)
Unknown 20 (29) 65 (45) 85 (40)
abi = abiraterone acetate plus prednisone; ECOG = Eastern Cooperative Oncology Group; LHLRa = luteinising hormone-releasing hormone agonist/antagonist;
PSA = prostate-speciﬁc antigen.
a Not collected due to regulatory reasons.
b Some patients who were treated with <24 wk of abiraterone acetate plus prednisone and/or with <4 wk of abiraterone acetate plus prednisone prior to the
start of enzalutamide treatment were included in the study prior to a protocol amendment to this inclusion criterion.
c One patient did not have metastatic disease as assessed by a scan performed during screening. However, the patient did present with nodal disease at diagnosis.
Nodal disease was confirmed by biopsy but it became immeasurable on the last scan before the patient entered the study and while he was still on abiraterone
acetate plus prednisone treatment.
d Response to treatment with abiraterone acetate plus prednisone was indicated by study site responses to whether the patient's largest 50% PSA decline was
observed while on treatment with abiraterone acetate plus prednisone and whether patients were responsive to treatment with abiraterone acetate plus
prednisone for metastatic prostate cancer.
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respectively). Thirty patients previously treated with
chemotherapy before abiraterone and 75 chemotherapy-
naïve patients had PSA progression.3.7. Time to start of another antineoplastic therapy
Overall, the median time to the start of other antineoplastic
therapy after the first dose of enzalutamide was 12mo (95%
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Fig. 1 – Kaplan-Meier plot of rPFS. The number of patients censored equalled the number of patients minus the number of events. Overall, 73 out of
214 patients were censored at data cut-off, at which 28 patients were still on treatment; 45 discontinued treatment without fulfilling radiographic
progression criteria and were alive at the time of data cut-off.
CI = confidence interval; cum = cumulative; rPFS = radiographic progression-free survival.
E U RO P E AN U RO LOGY 74 ( 2 018 ) 37 – 4 5 41CI: 9.9–14 mo), and was 10 mo (95% CI: [21_TD$DIFF]7–15 mo) for
patients previously treated with chemotherapy before
abiraterone and 13 mo (95% CI: 11–15 mo) for chemothera-
py-naïve patients. Overall, 108 patients initiated another
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of data cut-off). Thirty out of 145 (21%) patients were still on treatment
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Fig. 3 – Waterfall plot of maximum percentage decline in PSA.
PSA = prostate-specific antigen.
EU RO P E AN U RO L OGY 74 ( 2 018 ) 37 – 4 5423.8. Quality of life assessed by the European Quality of Life 5-
Domain Scale
Overall, the median score at baseline was 79 (quartiles: 60–
90), with a higher score indicating better health status. The
median baseline score was 75 (quartiles: 60–84) for
patients who were previously treated with chemotherapy
before abiraterone[4_TD$DIFF] and 80 (quartiles: 65–90) for chemo-
therapy-naïve patients. Generally, the European Quality of[(Fig._4)TD$FIG]Previous chemothe
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Fig. 4 – Kaplan-Meier plot of time[11_TD$DIFF]-to[11_TD$DIFF]-PSA progression. The number of patients
Out of 214 patients, 109 (51%) were censored (ie, did not have a PSA progressio
discontinued treatment at the time of data cut-off.
CI = confidence interval; cum. = cumulative; PSA = prostate-specific antigen.Life 5-Domain Visual Analogue Scale score did not change
greatly during the study and the median score remained
above 70% up to wk 49 (Supplementary Table 4).
3.9. Safety
In the overall safety population, 199 out of 214 (93%)
patients experienced a treatment-emergent adverse event
(TEAE) [22_TD$DIFF]: 93 (43%) experienced at least one grade 3 TEAE69
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n event at the time of data cut-off). Of these 109 patients, 94 (86%)
Table 2 – Treatment-emergent adverse events (TEAEs)
Adverse event, n (%) Total (n = 214)
Any TEAE 199 (93)
NCI-CTCAE grade 3 93 (43)
Drug-related 127 (59)
Drug-related NCI-CTCAE grade 3 18 (8.4)
TEAEs with death as an outcome 19 (8.9)
SAEa [12_TD$DIFF] 81 (38)
Drug-relatedb SAEa 8 (3.7)
Drug-related AE leading to study drug discontinuationb 22 (10)
Study drug discontinuation primarily due to an AE 17 (7.9)
AE = adverse event; NCI-CTCAE = National Cancer Institute Common
Terminology Criteria for Adverse Events; SAE = serious adverse event.
a Included SAEs upgraded by the sponsor based on review of the sponsor's
list of always serious terms, if any upgrade was done.
b Possible or probable, as assessed by the investigator or records where
relationship was missing.
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the investigator to be possibly or probably related to
enzalutamide (Table 2). Seventy (33%) patients reported an
adverse event (AE) leading to enzalutamide discontinua-
tion, and 22 (10%) had AEs that were considered to be
possibly or probably related to enzalutamide. A TEAE was
the primary reason for discontinuation of enzalutamide for
17 (7.9%) out of 214 patients. Study drug-related TEAEs
included fatigue (n = 57; 27%), decreased appetite (n = 27;
13%), asthenia (n = 19; 8.9%), nausea (n = 17; 7.9%), and
constipation (n = 12; 5.6%). Of 19 (8.9%) TEAEs that led to
death, one cause (cerebral infarction) was considered to be
possibly related to enzalutamide treatment. In the overall
population, 81 (38%) patients experienced at least one
serious AE, of which those reported by eight (3.7%) patients
were considered to be possibly related to enzalutamide
treatment. Falls were reported in nine (4.2%) patients. There
were no seizures reported.
4. Discussion
This studywas conducted to evaluate the efficacy and safety
of enzalutamide treatment in patients with mCRPC follow-
ing disease progression after at least 24 wk of abiraterone
treatment in order to fulfil a regulatory commitment. In the
overall population, the median duration of rPFS was 8.1 mo,
median survival timewas not reached, and the unconfirmed
PSA response rate was 27%. The antitumour activity with
enzalutamide in some patients appeared independent of
the use of chemotherapy before abiraterone treatment.
Reported AEs were consistent with the established safety
profile of enzalutamide and were as expected for the study
population. No further deterioration of quality of life, as
assessed by[23_TD$DIFF] the European Quality of Life 5-Domain[24_TD$DIFF] scale,
was reported during enzalutamide treatment.
Currently, there is no expert consensus on the use of
second-line treatment with enzalutamide or abiraterone in
symptomatic men who develop resistance after first-line
abiraterone or enzalutamide, respectively, due in part to the
absence of prospective clinical data in these settings
[13]. The prospective data herein show the antitumouractivity of enzalutamide in patients who progressed
following 24 wk of abiraterone and support the use of
enzalutamide in some patients in the postabiraterone
setting.
This large study evaluating the antitumour activity of
enzalutamide in patients with prostate cancer after
progression with abiraterone provides additional prospec-
tive data to previously published retrospective studies. In
retrospective analyses, patients treated with enzalutamide
following progression with abiraterone treatment of any
duration reported lower proportions of patients with 50%
decline in PSA from baseline ranging from 5.0–45.7%,
shorter PFS (range, 2.8–18.4 mo), and shorter OS (range,
7.1 mo–not yet reached) compared with the analysis herein
[14–21]. In another small, prospective study of 24 patients
with mCRPC who were treated with enzalutamide after
progression with docetaxel and abiraterone postche-
motherapy, PSA response of 50% was 17% and median
OSwas 4.8mo [22]. Additionally, two retrospective analyses
of chemotherapy-naïve patients with mCRPC treated with
enzalutamide after progressing with abiraterone reported
PSA responses50% of 11.0% and 34.0% and PFS durations of
3.6 mo and 4.7 mo [21,23–25]. A systematic analysis that
pooled data from 10 available clinical studies reported a
50% PSA response of 22.9% (range,19.3–27.1%),median PFS
of 3.1 mo (range, 1.4–4.9 mo), and median OS of 8.3 mo
(range, 2.9–10.6) [26].
The data herein indicate that approximately one-third of
patients who had progressed after abiraterone treatment
for 24 wk remained on the study after 9 mo of
enzalutamide treatment, with a median rPFS of 8.1 mo
and median time-to-PSA progression of 5.7 mo. The rPFS
may have been impacted by the censoring rate due to
patients not having radiological progression at time of trial
discontinuation. Moreover, per the study design, treatment
discontinuation was independent from PSA assessments
and enzalutamide treatment was often continued despite
the absence of a PSA response. It is also important to note
that rate of PSA decline, median rPFS, and median time-to-
PSA progression observed in the present study are inferior
to those observed in abiraterone-naïve men with mCRPC
treated with enzalutamide[5_TD$DIFF] [3,4,7] [25_TD$DIFF], suggesting a degree of
cross-resistance between these two agents.
Evidence of more modest antitumour activity of
abiraterone with the reverse sequence (ie, after progression
on enzalutamide) has also been previously reported by
small, retrospective analyses of patients with mCRPC who
had been enrolled in the AFFIRM study. In these analyses,
patients with mCRPC treated with abiraterone after
progressing with docetaxel and enzalutamide reported
PSA responses50% of 3% and 8%, median PFS of 2.7mo and
3.6 mo, and OS of 7.2 mo and 11.6 mo [11,12]. A similarly
modest clinical response was recently reported in a small
retrospective analysis of chemotherapy-naïve patients with
mCRPC who were treated with abiraterone after progres-
sion with enzalutamide, in which PSA response 50% was
7%, median PFS was 3.4 mo, andmedian OSwas 9.1 mo [27].
Overall, a better understanding of the biology of
abiraterone and enzalutamide resistance is key to optimise
EU RO P E AN U RO L OGY 74 ( 2 018 ) 37 – 4 544the use of these agents. A recent study reported the
conversion of abiraterone to themore activeD4 [14_TD$DIFF]-abiraterone
metabolite in mice and patients with prostate cancer
[28]. However, conversion of abiraterone to D4-abiraterone
is unlikely to have any impact on most enzalutamide-
resistant prostate cancer cells expressing constitutively
active androgen receptor splice variants (AR-SVs) that lack
the ligand-binding carboxy-terminal domain. AR-SVs are
believed to drive treatment resistance and may be
generated through increased AR splicing under selective
therapeutic pressure [29]. A recent study reported that AR-
SV expression results in resistance to both abiraterone and
enzalutamide [30].
This study's limitations include the single-arm, open-
label design, due to the absence of treatment options
available at the time of enrolment, and the censoring rate.
Furthermore, the study was not designed to provide
definitive answers regarding the most appropriate treat-
ment sequence, and additional studies are needed to
address this question. A phase 2, randomised study
(n = 202) evaluating sequencing for abiraterone and enza-
lutamide is currently ongoing (ClinicalTrials.gov,
NCT02125357). Symptomatic improvement and symptom-
atic deterioration, measured using patient-related out-
comes, were not comprehensively assessed in this trial.
5. Conclusions
In conclusion, enzalutamide showed antitumour activity in
some patients with mCRPC who had previously progressed
following at least 24 wk of abiraterone treatment, also
suggesting an important degree of cross-resistance be-
tween the two agents. Median rPFS in patients with prior
chemotherapy was consistent with previously reported
data for enzalutamide treatment of patients with mCRPC
who had received prior chemotherapy and abiraterone.
Reported TEAEs were consistent with the known safety
profile of enzalutamide.
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